Compared to Estimates, OrthoPediatrics (KIDS) Q4 Earnings: A Look at Key Metrics

Core Insights - OrthoPediatrics reported a revenue of $52.67 million for the quarter ended December 2024, reflecting a 40% increase year-over-year [1] - The earnings per share (EPS) was -$0.29, a decline from -$0.23 in the same quarter last year, with an EPS surprise of -31.82% compared to the consensus estimate of -$0.22 [1] - The revenue reported was slightly below the Zacks Consensus Estimate of $52.7 million, resulting in a surprise of -0.06% [1] Revenue Performance - Trauma and deformity product sales reached $36.41 million, exceeding the average estimate of $35.25 million, marking a year-over-year increase of 34.5% [4] - Sports medicine/other product sales were $0.63 million, falling short of the $1.12 million average estimate, representing a year-over-year decline of 29.2% [4] - Scoliosis product sales amounted to $15.63 million, surpassing the estimated $12.86 million, with a significant year-over-year increase of 61.8% [4] Stock Performance - Over the past month, OrthoPediatrics shares have returned -3.7%, compared to a -2.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]